The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics.
nikkei.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nikkei.com Daily Mail and Mail on Sunday newspapers.
She said the deal will enable BBL to attain a robust commercial engine in the developed markets of U.S. & Europe and will fast-track the company s journey of building a strong global brand. Biocon Biologics to Acquire Viatris Biosimilars Assets for Up to USD 3.335 Billion in Stock and Cash.